American College of Emergency Physicians
Understanding, Evaluating, and Managing irAs Associated with CAR T-Cell and BsAb Therapy in Multiple Myeloma
Tuesday, October 10
Time: 6:30 am–7:30 am | Registration, Breakfast and Symposium
Location: Grand Ballroom AB | Philadelphia Marriott Downtown
Speakers
Joshua Richter, MD
Associate Professor of Medicine
Tisch Cancer Institute
Director, Multiple Myeloma
Blavatnick Family Chelsea Medical Center
Mount Sinai Hospital
New York, New York
Monica Wattana, MD
Director of Education, Oncologic EM Fellowship Director
Associate Professor in the Department of Emergency Medicine
MD Anderson
Houston, Texas
Symposium Information
Multiple myeloma (MM), the second most common hematological malignancy in the world, affects 1 to 5 out of 100,000 individuals per year primarily in patients 65 years of age or older. There is currently no cure and patients reaching complete response (CR) to treatment will eventually relapse. MM patients with relapsing and/or refractory (R/R) disease are exposed for prolonged periods of time to multiple drugs in varying combinations, which increases their risk of developing toxicity and treatment-related adverse events (TRAEs). With the increasing implementation of novel therapies, including CAR T-cell therapy and bispecific antibodies (BsAbs), to the growing treatment armamentarium for MM, emergency medical physicians, advanced practice practitioners (APPs), and other emergency medicine health professionals must remain apprised of any and all TRAEs. Clinicians must be prepared to both quickly and accurately diagnose and treat life-threatening events including immune effector cell-associated neurotoxicity syndrome neurotoxicity (ICANS) and cytokine release syndrome (CRS). With these challenges in mind, this symposium will focus on the safety and efficacy of current and emerging immunotherapies, and patient-specific strategies related to risk factors, toxicities, and AE management to assist emergency providers in mitigating untoward TRAEs as they apply to MM.
Learning Objectives
- Evaluate recent real-world clinical data of newer and emerging immunotherapeutic options, including CAR T-cell therapy and BsAbs, for the treatment of R/R MM and their potential implications in the development of TRAEs
- Accurately recognize, diagnose, treat, and manage the most common hematological and non-hematological toxicities and TRAEs in patients affected by and treated for MM
- Understand current guidelines and protocols available for TRAEs in MM patients
- Incorporate and implement a multidisciplinary team (MDT) approach to improve MM patient outcomes and quality of life
Commercial Support
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Continuing Education
In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.
Physicians
HMP Education designates this internet live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
This continuing nursing education internet live activity awards 1.0 contact hour(s).
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour(s).
Nurse Practitioners
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
Physician Assistants
HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with the AAPA CME Criteria. This internet live activity is designated for 1.0 AAPA Category 1 credit(s). PAs should only claim credit commensurate with the extent of their participation.
